Controlled release of magnesium ions shapes osteoporotic bone repair

Nature Reviews Rheumatology, Published online: 31 July 2026; doi:10.1038/s41584-026-01418-xAn osteoimmunomodulatory implant that enables finely tuned release of magnesium ions could offer a way to enhance osteoporotic bone repair.

dlvr.it

PD-1 agonism puts the brakes on pathogenic T cell responses in RA

Nature Reviews Rheumatology, Published online: 30 July 2026; doi:10.1038/s41584-026-01417-yPD-L2-mediated activation of PD-1 signalling in rheumatoid arthritis suppresses pro-inflammatory cytokine production and regulates pathogenic B cell responses.

dlvr.it

Navigating evidence-based recommendations for the management of systemic sclerosis

Nature Reviews Rheumatology, Published online: 04 August 2026; doi:10.1038/s41584-026-01416-zIn this Review article, the authors compare current guidelines for systemic sclerosis, including recommendations for systemic sclerosis-associated interstitial lung disease. They emphasize the importance of alignment across guidelines to support informed clinical decision-making and patient care.

dlvr.it

Advances in the treatment of eosinophilic granulomatosis with polyangiitis

Nature Reviews Rheumatology, Published online: 04 August 2026; doi:10.1038/s41584-026-01406-1The development of targeted therapeutics has transformed the management of eosinophilic granulomatosis with polyangiitis (EGPA). This Review explores the role of these new therapies, as well as that of the still-relevant historical treatments, for the induction and maintenance of remission in EGPA.

dlvr.it

Sex-dependent mechanisms in rheumatic diseases

Nature Reviews Rheumatology, Published online: 03 August 2026; doi:10.1038/s41584-026-01405-2Sex-dependent mechanisms, including sex hormones, X chromosome biology, epigenetic regulation, microbiome dynamics and antiviral immunity, interact to shape immune responses and contribute to differences in susceptibility, manifestations and treatment outcomes in rheumatic diseases, highlighting opportunities for precision, sex-informed therapeutic strategies.

dlvr.it

When less is more: loss of IRAK2 signalling promotes inflammation

Nature Reviews Rheumatology, Published online: 03 August 2026; doi:10.1038/s41584-026-01414-1The identification of IRAK2 deficiency reveals how impaired Myddosome signalling can paradoxically promote interferon-driven inflammation, which expands the spectrum of monogenic immune dysregulation and underscores the importance of detecting structural variants in unsolved inborn errors of immunity.

dlvr.it

Metabolic exhaustion and immune ageing in rheumatoid arthritis

Nature Reviews Rheumatology, Published online: 03 August 2026; doi:10.1038/s41584-026-01402-5This Review examines how ageing-driven metabolic exhaustion in T cells and macrophages promotes organelle dysfunction, inflammatory cell death and chronic synovitis in rheumatoid arthritis.

dlvr.it

AI detects signs of inflammatory arthritis in hand images

Nature Reviews Rheumatology, Published online: 28 July 2026; doi:10.1038/s41584-026-01415-0Automatic assessment of joints by artificial intelligence (AI) or computer vision using photographs or videos can support the detection and/or monitoring of arthritis. Ideally, these data combined with other digital biomarkers, including patient-reported outcomes, can be implemented into clinical workflows for remote patient monitoring.

dlvr.it

From psoriatic plaque to synovium: decoding the skin–joint axis in psoriatic arthritis

Nature Reviews Rheumatology, Published online: 31 July 2026; doi:10.1038/s41584-026-01412-3This Review synthesizes evidence for a skin–joint axis in psoriatic arthritis (PsA), highlighting key mechanisms that might drive the transition from psoriasis to PsA. The authors emphasize that further research into this axis could be important for identifying biomarkers, informing patient stratification and predicting which patients will progress to PsA.

dlvr.it

Controlled release of magnesium ions shapes osteoporotic bone repair

Nature Reviews Rheumatology, Published online: 31 July 2026; doi:10.1038/s41584-026-01418-xAn osteoimmunomodulatory implant that enables finely tuned release of magnesium ions could offer a way to enhance osteoporotic bone repair.

dlvr.it

PD-1 agonism puts the brakes on pathogenic T cell responses in RA

Nature Reviews Rheumatology, Published online: 30 July 2026; doi:10.1038/s41584-026-01417-yPD-L2-mediated activation of PD-1 signalling in rheumatoid arthritis suppresses pro-inflammatory cytokine production and regulates pathogenic B cell responses.

dlvr.it

AI detects signs of inflammatory arthritis in hand images

Nature Reviews Rheumatology, Published online: 28 July 2026; doi:10.1038/s41584-026-01415-0Automatic assessment of joints by artificial intelligence (AI) or computer vision using photographs or videos can support the detection and/or monitoring of arthritis. Ideally, these data combined with other digital biomarkers, including patient-reported outcomes, can be implemented into clinical workflows for remote patient monitoring.

dlvr.it

Hypoxia as an amplifier of synovial inflammation in rheumatoid arthritis

Nature Reviews Rheumatology, Published online: 22 July 2026; doi:10.1038/s41584-026-01397-zIn rheumatoid arthritis (RA) a hypoxic gradient develops in the synovium, which shapes inflammation and immune responses. In this Review, the authors provide insights into the role of hypoxia in the pathogenesis of RA, discuss its role in the wider integrated signalling network that drives inflammation and highlight how hypoxia can be targeted therapeutically to treat RA.

dlvr.it

Hypoxia as an amplifier of synovial inflammation in rheumatoid arthritis

Nature Reviews Rheumatology, Published online: 22 July 2026; doi:10.1038/s41584-026-01397-zIn rheumatoid arthritis (RA) a hypoxic gradient develops in the synovium, which shapes inflammation and immune responses. In this Review, the authors provide insights into the role of hypoxia in the pathogenesis of RA, discuss its role in the wider integrated signalling network that drives inflammation and highlight how hypoxia can be targeted therapeutically to treat RA.

dlvr.it

Secukinumab shows diverging efficacy in PMR and GCA

Nature Reviews Rheumatology, Published online: 16 July 2026; doi:10.1038/s41584-026-01413-2In two phase III trials, secukinumab improved rates of sustained remission and reduced glucocorticoid use in polymyalgia rheumatica but did not improve outcomes in giant cell arteritis.

dlvr.it

Lymph node ‘hideouts’ shield B cells from antibody therapy

Nature Reviews Rheumatology, Published online: 13 July 2026; doi:10.1038/s41584-026-01408-zLymph node architecture sequesters B cells away from effector cells, limiting antibody-mediated depletion and highlighting tissue remodelling as a strategy to improve therapeutic responses.

dlvr.it

Secukinumab shows diverging efficacy in PMR and GCA

Nature Reviews Rheumatology, Published online: 16 July 2026; doi:10.1038/s41584-026-01413-2In two phase III trials, secukinumab improved rates of sustained remission and reduced glucocorticoid use in polymyalgia rheumatica but did not improve outcomes in giant cell arteritis.

dlvr.it

Advances in targeting IL-1 family cytokines for the treatment of inflammatory diseases

Nature Reviews Rheumatology, Published online: 09 July 2026; doi:10.1038/s41584-026-01395-1This Review provides an update on the interleukin 1 (IL-1) family of cytokines in inflammatory and rheumatic diseases. The authors discuss advances in mechanistic understanding and highlight therapeutic developments in targeting this family of cytokines.

dlvr.it

Lymph node ‘hideouts’ shield B cells from antibody therapy

Nature Reviews Rheumatology, Published online: 13 July 2026; doi:10.1038/s41584-026-01408-zLymph node architecture sequesters B cells away from effector cells, limiting antibody-mediated depletion and highlighting tissue remodelling as a strategy to improve therapeutic responses.

dlvr.it

Going beyond cycling versus swapping for treatment sequencing in psoriatic arthritis

Nature Reviews Rheumatology, Published online: 07 July 2026; doi:10.1038/s41584-026-01404-3After treatment failure in psoriatic arthritis (PsA), choosing the next therapy involves more than simply cycling within a drug class or switching to another. Treatment sequencing is increasingly guided by dynamic, individualized strategies that account for a patient’s long-term care pathway.

dlvr.it

Obexelimab reduces the risk of IgG4-RD flare

Nature Reviews Rheumatology, Published online: 07 July 2026; doi:10.1038/s41584-026-01410-5In the phase III INDIGO trial, B cell inhibition with obexelimab reduced the risk of disease flare and exposure to glucocorticoids in patients with IgG4-related disease.

dlvr.it

Targeting P2X7R on synovial fibroblasts to treat refractory RA

Nature Reviews Rheumatology, Published online: 07 July 2026; doi:10.1038/s41584-026-01411-4New research implicates P2X7 receptor in synovial inflammation and suggests that it could be a promising therapeutic target in refractory rheumatoid arthritis.

dlvr.it

Dysfunctional UBA1-mutated myeloid cells promote inflammation in VEXAS syndrome

Nature Reviews Rheumatology, Published online: 06 July 2026; doi:10.1038/s41584-026-01407-0Findings show that UBA1-mutated myeloid cells are dysfunctional and highly susceptible to cell death, which promotes inflammation in VEXAS syndrome.

dlvr.it

Advances in targeting IL-1 family cytokines for the treatment of inflammatory diseases

Nature Reviews Rheumatology, Published online: 09 July 2026; doi:10.1038/s41584-026-01395-1This Review provides an update on the interleukin 1 (IL-1) family of cytokines in inflammatory and rheumatic diseases. The authors discuss advances in mechanistic understanding and highlight therapeutic developments in targeting this family of cytokines.

dlvr.it

Going beyond cycling versus swapping for treatment sequencing in psoriatic arthritis

Nature Reviews Rheumatology, Published online: 07 July 2026; doi:10.1038/s41584-026-01404-3After treatment failure in psoriatic arthritis (PsA), choosing the next therapy involves more than simply cycling within a drug class or switching to another. Treatment sequencing is increasingly guided by dynamic, individualized strategies that account for a patient’s long-term care pathway.

dlvr.it

Joint-specific susceptibility to inflammation is determined in utero

Nature Reviews Rheumatology, Published online: 02 July 2026; doi:10.1038/s41584-026-01403-4Findings indicate that stromal niches established during development dictate joint-specific susceptibility to inflammation in arthritis.

dlvr.it

Dapirolizumab pegol improves SLE disease activity in phase III trial

Nature Reviews Rheumatology, Published online: 07 July 2026; doi:10.1038/s41584-026-01409-yThe results of a 48-week, randomized, placebo-controlled trial suggest that the novel CD40 ligand inhibitor dapirolizumab pegol could have clinical benefits for patients with systemic lupus erythematosus.

dlvr.it

Targeting P2X7R on synovial fibroblasts to treat refractory RA

Nature Reviews Rheumatology, Published online: 07 July 2026; doi:10.1038/s41584-026-01411-4New research implicates P2X7 receptor in synovial inflammation and suggests that it could be a promising therapeutic target in refractory rheumatoid arthritis.

dlvr.it

Obexelimab reduces the risk of IgG4-RD flare

Nature Reviews Rheumatology, Published online: 07 July 2026; doi:10.1038/s41584-026-01410-5In the phase III INDIGO trial, B cell inhibition with obexelimab reduced the risk of disease flare and exposure to glucocorticoids in patients with IgG4-related disease.

dlvr.it